Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA

Nam, Jackie; Winthrop, Kevin; Vollenhoven, R F van; Pavelka, Karel; Valesini, Guido; Hensor, Elizabeth M A; Worthy, Gillian; Landewé, Robert; Smolen, Josef S.; Emery, Paul; Buch, Maya H

doi:10.1136/ard.2009.126573

Cited by 351 publications

(241 citation statements)

References 89 publications

Supporting

Mentioning

213

Contrasting

Unclassified

Order By: Relevance

“…Randomized controlled clinical trials have established that the addition of anti-tumor necrosis factor (TNF) agents to MTX therapy in patients with an inadequate response to MTX results in significant improvements in clinical, radiographic, and functional outcomes 4,5,6,7,8,9,10,11 . Current recommendations for patients with poor prognostic factors suggest treatment with MTX for 3 to 6 months before considering the addition of biologic DMARD therapy 12 , but some rheumatologists continue MTX for longer periods before considering the addition of biologic therapy 13,14 .…”

mentioning

confidence: 99%

Clinical, Functional, and Radiographic Benefits of Longterm Adalimumab Plus Methotrexate: Final 10-year Data in Longstanding Rheumatoid Arthritis

Keystone

Heijde²,

Kavanaugh³

et al. 2013

J Rheumatol

View full text Add to dashboard Cite

Objective.To examine the longterm effectiveness and safety of adalimumab in patients with longstanding rheumatoid arthritis (RA) and an inadequate response to methotrexate (MTX), and to assess the effect of a 1-year delay in initiation of combination therapy.Methods.DE019 was a 1-year randomized controlled trial (RCT) in which patients received adalimumab 20 mg weekly, adalimumab 40 mg every other week (eow), or placebo; all received concomitant MTX. Patients completing the RCT could receive open-label adalimumab 40 mg eow + MTX for an additional 9 years. Clinical, functional, and radiographic outcomes were assessed using composite measures of disease activity (e.g., American College of Rheumatology responses, 28-joint Disease Activity Score with C-reactive protein, Simplified Disease Activity Index), Health Assessment Questionnaire-Disability Index, and the modified total Sharp score (mTSS), respectively.Results.Of the 619 patients randomized, 457 entered the open-label extension; 202 completed 10 years. At Year 10, patients demonstrated effective disease control and inhibition of radiographic progression. Differences in clinical and functional responses between adalimumab + MTX and placebo + MTX observed during the RCT became less apparent at Year 10. Still, patients who initially received adalimumab + MTX had significantly lower mean ΔmTSS at Year 10 compared with patients who initially received placebo + MTX. No new safety signals arose following up to 10 years of adalimumab + MTX exposure.Conclusion.During up to 10 years of treatment with adalimumab + MTX, patients with longstanding RA experienced effective disease control with no change to the expected safety profile. A 1-year delay in receipt of adalimumab + MTX was associated with reduced effectiveness, suggesting that a window of opportunity to prevent irreversible damage exists even in a population with established RA.

show abstract

mentioning

confidence: 99%

Clinical, Functional, and Radiographic Benefits of Longterm Adalimumab Plus Methotrexate: Final 10-year Data in Longstanding Rheumatoid Arthritis

Keystone

Heijde²,

Kavanaugh³

et al. 2013

J Rheumatol

View full text Add to dashboard Cite

show abstract

“…La méta-analyse de Leombruno et al [37] n'a pas non plus mis en évidence de différence significative entre les patients sous anti-TNF et les patients sous nbDMARDs. Plusieurs études [31,38,39] ont conclu à une augmentation du risque infectieux au cours des six premiers mois de traitement, le temps que la maladie inflammatoire soit stabilisée. La PR représente un risque inhérent d'infection imputé au dysfonctionnement du système immunitaire.…”

Section: Discussionunclassified

Évaluation du rapport bénéfice-risque de la suspension des anti-TNF alpha en chirurgie orale

Pannérec

Catros

Fricain

2014

Med Buccale Chir Buccale

View full text Add to dashboard Cite

“…Multiple studies have demonstrated significant benefits of early treatment with TNF-inhibitors combined with methotrexate (27)(28)(29). Other FDA-approved biologic agents for treating moderate-to-severe RA include abatacept, rituximab, and tocilizumab (30)(31)(32)(33). However, all biologic agents carry an increased risk of infections.…”

Section: Current Biological Therapies For Ramentioning

confidence: 99%

Stem Cell-Based Cellular Therapy in Rheumatoid Arthritis

Haque¹,

Lei²,

Xiong³

et al. 2012

Autoimmune Diseases - Contributing Factors, Specific Cases of Autoimmune Diseases, and Stem Cell and Other Therapies

View full text Add to dashboard Cite

Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA

Abstract: There is good evidence for the efficacy of biological agents in patients with RA. Safety data confirm an increased risk of bacterial infection and TB with TNFi compared with conventional DMARDs.

Cited by 351 publications

References 89 publications

Clinical, Functional, and Radiographic Benefits of Longterm Adalimumab Plus Methotrexate: Final 10-year Data in Longstanding Rheumatoid Arthritis

Clinical, Functional, and Radiographic Benefits of Longterm Adalimumab Plus Methotrexate: Final 10-year Data in Longstanding Rheumatoid Arthritis

Évaluation du rapport bénéfice-risque de la suspension des anti-TNF alpha en chirurgie orale

Stem Cell-Based Cellular Therapy in Rheumatoid Arthritis

Contact Info

Product

Resources

About